There are a lot of studies that have been completed and many more that are awaiting start. You can find studies on what cannabis at ClinicalTrial.Gov and search for Cannabis – Marijuana – Cannabinoids and other terms and come up with all kinds of results.
Where you can really find heads up is the Federal Register. There you will find people that are applying to obtain licenses from the DEA to handle Cannabis (search for 7360 the DEA code for Marijuana). When they apply under law there is a comment period where persons, organizations and companies can make comment on the application. Most of the time there is no comment made and then the DEA decides if they are going to grant or not. However if there are comments made then the DEA incorporates these comments into their reply to the application when they grant or deny.
Finally there is also PubMed where you can search all kinds of different things. You will find information like this from Medical Marijuana: Just the Beginning of a Long, Strange Trip? C.D. Ciccone, PT, PhD, FAPTA, Department of Physical Therapy, Ithaca College.
Although there is still a need for randomized controlled clinical trials, preliminary studies have suggested that medical marijuana and related cannabinoids may be beneficial in treating chronic pain, inflammation, spasticity, and other conditions seen commonly in physical therapist practice. Physical therapists should therefore be aware of the options that are available for patients considering medical marijuana, and be ready to provide information for these patients. Clinicians should also be aware that marijuana can produce untoward effects on cognition, coordination, balance, and cardiovascular and pulmonary function, and be vigilant for any problems that may arise if patients are using cannabinoids during physical rehabilitation.
So it’s clear from the information available that THC, Cannabidiol along with all of the other cannabinoids and substances in Plant based Cannabis
- does not produce any unknown adverse effects or other effects that are extremely common in Pharmaceutical preparations.
- does not have an unattainable LD-50 level (another indicator of overall safety).
- has shown therapeutic actions that are beneficial to many patients.
So there is no reason why companies should need to rely on synthetic versions of the various cannabinoid and plant compounds. They should be allowed to use the whole plant and the various strains of the plant to treat any condition.
Given the safety of the substances, the variety of administration methods there is no reason not to use trial and error. As has been seen with Charlotte’s Web there are strains that work better for some conditions. As the science of cannabis expands so will the introduction of strain specific treatments. There isn’t a reason to not be able to move from one concentration of substances to another just like doctors change medications that aren’t producing the desired results to ones that do work.
Not every medication works for every person. It happens all the time in medicine, a doctor prescribes something and it just doesn’t work or produce the desired effect. Change drugs to something similar and bingo it works. Doctors can’t explain it, Pharmacy companies can’t explain it, the FDA can’t explain it. Given the great number of varieties already developed and those that will be developed that lots of conditions can be treated with cannabis.
Cannabis has a long history of being safe and effective. There is no reason that all cannabis can’t be used by patients because of this safety when used. Unlike other medications that can produce irreversible affects, cannabis just doesn’t do that to patients.